top of page
Search

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in NASH

  • Writer: SBIJI Innovation
    SBIJI Innovation
  • Apr 28, 2021
  • 1 min read

The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation


TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibrosis.

 
 
 

Recent Posts

See All

Comments


A Member firm of SBI Group, Japan

© 2020 SBI JI Innovation Advisory Ltd. All rights reserved

bottom of page